Recently, there have been reports of the difficulty in vaccination against tetravalent human papilloma virus for the prevention of cervical cancer. At the same time, 'the suspension of the supply of the nine-valent HPV vaccine in the Hong Kong market' has also aroused much attention from the community. survey.
'A seedling is hard to find' : Cross-country vaccination
'I have ordered an inoculation of the quadrivalent HPV vaccine since the end of 2017 at a community health center near my home. I haven't heard any news in half a year. Shanghai has not yet begun to supply the newly approved nine-valent HPV vaccine. I simply want to inoculate nine in Hong Kong. HPV vaccine. 'Shanghai citizen Sun Huining said.
However, after she contacted several medical institutions, she found that the supply situation in Hong Kong was not optimistic. Some people even if they received the first shot, they could not guarantee timely inoculation of the second needle. After some consideration, she also chose this route.
Sun Huining introduced that she inoculated a nine-price HPV vaccine at a public medical institution in South Korea. The total of three needles was about 800,000 won (over 4,700 yuan). At the time of inoculation of the first needle, she paid the full amount as required and received a bid. There is a written certificate issued by the supplier Merck.
It is understood that in the Mainland, the nine-valent HPV vaccine is suitable for vaccination of women aged 16 to 26 years. In Hong Kong, the vaccine is applicable to people over 9 years of age (not limited to men and women) and in Korea to people aged 9-26 (not limited to men and women). Although the applicable ages of vaccines in different regions are different, the management methods may also be different. However, as long as they can be achieved, many people prefer to “get closer”.
Sun Hui-Jin admitted frankly that he also wanted to use domestic vaccines to save time and effort, but the main reason for going abroad to vaccinate is not to wait. Looking at the long queue of quadrivalent HPV vaccines, he feared that after the supply of nine-valent HPV vaccines in many places in China, Waiting for a long time. It is worth mentioning that, in this 'travel', Sun Huining also met several Chinese young friends of her age. When communicating, I found that everyone's thoughts are basically the same: 'early morning peace of mind'.
Merck East: Will accelerate production and increase production capacity
Currently, the globally marketed HPV vaccines are divalent, tetravalent, and nine-valent. The 'valence' represents the type of virus that can be prevented by the vaccine. The bivalent vaccine can prevent HPV16 and HPV18 virus infections. The tetravalent vaccine can prevent 6, 11 , 16, 18 HPV infection, nine-valent vaccine is more than five kinds of prevention on the basis of four. According to reports, bivalent and tetravalent vaccine, can prevent 84.5% of the risk of cervical cancer, 9-valent vaccine can prevent 92.1% of the Cervical cancer.
Among them, the bivalent HPV vaccine was provided by GlaxoSmithKline, a quadrivalent, nine-valent HPV vaccine was provided by Merck & Co.
-- In an interview with the Xinhua News Agency’s “China Net Affairs” reporter, Merck said that for the four prices in the Mainland, the shortage of nine-valent HPV vaccine in Hong Kong will accelerate production. The vaccine production process is complex and the production cycle is long, ensuring the quality and safety of the vaccine. Under the premise of, the company is increasing investment to increase production capacity and strengthen the supply of HPV vaccine.
According to MSD, since November 2017, the company’s Hong Kong team has been advising doctors to keep follow-up injections for consumers who have been vaccinated with the first dose of HPV vaccine. Currently, the 9-valent HPV vaccine is still available in the Hong Kong market. MSD Hong Kong Aspects will announce further information in a timely manner.
- According to Merck News, according to the results of the price negotiation of the second type of vaccine supplement project in Hainan Province, the bid price for the 9-valent HPV vaccine was 1298 yuan/support. At present, the recruitment of standards for the provinces and cities is under discussion, once more The exact information will be communicated to the public in a timely manner through the publicity of the relevant government.
'The nine-price HPV vaccine was quickly approved for listing based on the relevant regulatory authorities' adoption of the clinical trial data of the nine-price HPV vaccine before it was marketed on overseas markets. At present, we are working with national requirements to apply for clinical trials in other age groups.' The Merck side said.
- There is no shortage of bivalent HPV vaccine, and the current market supply is normal. GlaxoSmithKline said that since the 'Shriver' was launched in July 2017, the situation of vaccination among women of the right age has responded well. It was jointly launched with Ali Health. In the past 9 months since the adult vaccine service project, there were more than 300,000 potential vaccinators through online consultation, and the actual number of people making a reservation reached 50,000.
'Tendering has been completed in 28 provinces and cities across the country. According to the bidding schedule of each province, the remaining provinces will be invited to complete the tender. China is one of our key markets and will spare no effort to ensure adequate and stable supply of cervical cancer vaccines to meet the majority of Vaccination needs of school-age women. 'The GlaxoSmithKline side said.
Tertiary prevention: Screening and early treatment are still indispensable
As a common malignancy that seriously threatens women's health, cervical cancer ranks high among female malignant tumors in the world. Dr. Zhi Li from the Shanghai Municipal Center for Disease Control and Prevention immunization planning said that vaccination is for women, especially for high-risk groups. Cancer is of great significance.
Zhao Dong, director of the Department of Cerviology at Shanghai First Maternal and Child Health Hospital, said that HPV vaccination is mainly for the prevention of high-risk HPV infection in high-risk groups (mainly young women).
It is understood that the domestically approved bivalent, tetravalent, and nine-valent HPV vaccines are applicable to women aged 9 to 25, 20 to 45, and 16 to 26, respectively. The vaccine is usually administered in three injections, for a total of 6 Months can be effective.
Regarding the applicable population of some vaccines and the timetable for future vaccination, many people have appealed that although the approval of the mainland's nine-valence HPV vaccine is fast, it is hoped that the applicable age of the nine-valent HPV vaccine can be released more quickly and can be included in the insurance coverage. Most importantly, we hope that the relevant manufacturers can increase their production capacity in time to meet the needs of more people.
In the view of many industry experts, there are hundreds of types of HPV viruses. No matter what kind of HPV vaccine, it cannot cover all carcinogenic HPV. From first-level vaccination to secondary enhanced cervical cancer screening and third-grade Early diagnosis and treatment of advanced cervical cancer three-stage prevention system is a long way to go.
